Ambelvist (gadoquatrane)
Bayer HealthCare
ApprovedJun 12, 2026
Marketer take
A gadolinium MRI contrast agent entering a commoditized category, so radiology departments and group purchasing decisions matter more than referring physicians.
- Sponsor company
- Bayer HealthCare
- Indication
- To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
- Therapeutic area
- Diagnostic imaging
- Event
- FDA approval
- Date
- Jun 12, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?